Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 10/20 | 0.60 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.55 |
| ▸ | IL2 | P60568 | 3/20 | 0.50 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592559 | 0.93 | MAP4K1 (0.55) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592652 | 0.93 | MAP4K1 (0.55) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592566 | 0.92 | MAP4K1 (0.65) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592622 | 0.90 | MAP4K1 (0.59) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21593057 | 0.89 | MAP4K1 (0.66) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592683 | 0.89 | TNIK (0.69) | MAP4K1TNIKCAMKK2PIK3CG | |
| SCHEMBL21592924 | 0.87 | MAP4K1 (0.60) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592831 | 0.86 | MAP4K1 (0.57) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592684 | 0.86 | MAP4K1 (0.69) | MAP4K1TNIKCAMKK2IL2MAP3K11 | |
| SCHEMBL21592569 | 0.85 | MAP4K1 (0.62) | MAP4K1TNIKCAMKK2IL2MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |